431 related articles for article (PubMed ID: 29315388)
1. Galectin-3 and cancer stemness.
Nangia-Makker P; Hogan V; Raz A
Glycobiology; 2018 Apr; 28(4):172-181. PubMed ID: 29315388
[TBL] [Abstract][Full Text] [Related]
2. Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain.
Kang HG; Kim DH; Kim SJ; Cho Y; Jung J; Jang W; Chun KH
Oncotarget; 2016 Oct; 7(42):68229-68241. PubMed ID: 27626163
[TBL] [Abstract][Full Text] [Related]
3. Galectin-3 modulates the EGFR signalling-mediated regulation of Sox2 expression via c-Myc in lung cancer.
Kuo HY; Hsu HT; Chen YC; Chang YW; Liu FT; Wu CW
Glycobiology; 2016 Feb; 26(2):155-65. PubMed ID: 26447186
[TBL] [Abstract][Full Text] [Related]
4. Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis.
Marquardt S; Solanki M; Spitschak A; Vera J; Pützer BM
Semin Cancer Biol; 2018 Dec; 53():90-109. PubMed ID: 29966677
[TBL] [Abstract][Full Text] [Related]
5. Galectin-3 in angiogenesis and metastasis.
Funasaka T; Raz A; Nangia-Makker P
Glycobiology; 2014 Oct; 24(10):886-91. PubMed ID: 25138305
[TBL] [Abstract][Full Text] [Related]
6. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
Yan Y; Zuo X; Wei D
Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
[TBL] [Abstract][Full Text] [Related]
7. microRNAs in cancer stem cells: Biology, pathways, and therapeutic opportunities.
Asadzadeh Z; Mansoori B; Mohammadi A; Aghajani M; Haji-Asgarzadeh K; Safarzadeh E; Mokhtarzadeh A; Duijf PHG; Baradaran B
J Cell Physiol; 2019 Jul; 234(7):10002-10017. PubMed ID: 30537109
[TBL] [Abstract][Full Text] [Related]
8. Cell surface galectin-3 defines a subset of chemoresistant gastrointestinal tumor-initiating cancer cells with heightened stem cell characteristics.
Ilmer M; Mazurek N; Byrd JC; Ramirez K; Hafley M; Alt E; Vykoukal J; Bresalier RS
Cell Death Dis; 2016 Aug; 7(8):e2337. PubMed ID: 27512958
[TBL] [Abstract][Full Text] [Related]
9. Nuclear transport of galectin-3 and its therapeutic implications.
Funasaka T; Raz A; Nangia-Makker P
Semin Cancer Biol; 2014 Aug; 27():30-8. PubMed ID: 24657939
[TBL] [Abstract][Full Text] [Related]
10. Targeting signal transduction pathways of cancer stem cells for therapeutic opportunities of metastasis.
Iqbal W; Alkarim S; AlHejin A; Mukhtar H; Saini KS
Oncotarget; 2016 Nov; 7(46):76337-76353. PubMed ID: 27486983
[TBL] [Abstract][Full Text] [Related]
11. The role of galectin-3 in cancer drug resistance.
Fukumori T; Kanayama HO; Raz A
Drug Resist Updat; 2007 Jun; 10(3):101-8. PubMed ID: 17544840
[TBL] [Abstract][Full Text] [Related]
12. Cancer stem cells: perspectives for therapeutic targeting.
Maccalli C; De Maria R
Cancer Immunol Immunother; 2015 Jan; 64(1):91-7. PubMed ID: 25104304
[TBL] [Abstract][Full Text] [Related]
13. Galectin-3 augments tumor initiating property and tumorigenicity of lung cancer through interaction with β-catenin.
Chung LY; Tang SJ; Wu YC; Sun GH; Liu HY; Sun KH
Oncotarget; 2015 Mar; 6(7):4936-52. PubMed ID: 25669973
[TBL] [Abstract][Full Text] [Related]
14. Galectin-3 promotes CXCR2 to augment the stem-like property of renal cell carcinoma.
Huang CS; Tang SJ; Lee MH; Chang Wang CC; Sun GH; Sun KH
J Cell Mol Med; 2018 Dec; 22(12):5909-5918. PubMed ID: 30246456
[TBL] [Abstract][Full Text] [Related]
15. Smad inhibitor induces CSC differentiation for effective chemosensitization in cyclin D1- and TGF-β/Smad-regulated liver cancer stem cell-like cells.
Xia W; Lo CM; Poon RYC; Cheung TT; Chan ACY; Chen L; Yang S; Tsao GSW; Wang XQ
Oncotarget; 2017 Jun; 8(24):38811-38824. PubMed ID: 28415588
[TBL] [Abstract][Full Text] [Related]
16. Role of Galectins in Tumors and in Clinical Immunotherapy.
Chou FC; Chen HY; Kuo CC; Sytwu HK
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29389859
[TBL] [Abstract][Full Text] [Related]
17. Non-classical role of Galectin-3 in cancer progression: translocation to nucleus by carbohydrate-recognition independent manner.
Kim SJ; Chun KH
BMB Rep; 2020 Apr; 53(4):173-180. PubMed ID: 32172730
[TBL] [Abstract][Full Text] [Related]
18. Unraveling galectin-1 as a novel therapeutic target for cancer.
Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Neuzillet C; Albert S; Raymond E; Faivre S
Cancer Treat Rev; 2014 Mar; 40(2):307-19. PubMed ID: 23953240
[TBL] [Abstract][Full Text] [Related]
19. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine-phosphorylated galectin-3 protein is resistant to prostate-specific antigen (PSA) cleavage.
Balan V; Nangia-Makker P; Kho DH; Wang Y; Raz A
J Biol Chem; 2012 Feb; 287(8):5192-8. PubMed ID: 22232548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
